Dr. Ron DeMatteo GIST specialist surgeon Dr. Ron DeMatteo, along with colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC), has published a new paper in the April issue of Cancer Research with potentially [...]
MSKCC is launching a clinical trial that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients
The GIST Group of Switzerland awarded its science prize for the third time on November 22, 2012. It has been awarded ex aequo to Dr. Daniel Perez, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA, and Dr. Michael Montemurro, CHUV Lausanne/University Hospital Zurich.
A new clinical trial combining targeted therapy with immunotherapy has just opened at Memorial Sloan-Kettering Cancer Center (MSKCC). This trial is the culmination of extensive pre-clinical investigations by MSKCC researchers. Although treatment with Gleevec [...]